We're investing in a future where bioengineering has industrial scale and speed, and today’s barely conceivable medicines are routine.
Investment Stage: Series B; Series D
Portfolio 54
| Date | Name | Website | Total Raised | Location |
| 10.07.2026 | Fore Bio | fore.bio | $180.4M | United Sta... |
| 10.06.2026 | SonoThera,... | sonothera.com | $310.75M | United Sta... |
| 10.02.2026 | CORXEL Pha... | corxelbio.com | $287M | - |
| 17.12.2025 | SanegeneBi... | sanegenebio.com | $110M | China |
| 16.12.2025 | Aeovian Ph... | aeovian.com | $105M | United Sta... |
| 18.11.2025 | Solve Ther... | solvetx.com | $120M | - |
| 02.11.2025 | TORL | torlbio.com | $158M | United Sta... |
| 02.11.2025 | Alebund Ph... | alebund.com | - | China, Sha... |
| 26.03.2025 | Tempero Bi... | temperobio.com | $70M | United Sta... |
| 26.03.2025 | F2G | f2g.com | $291M | United Kin... |
Show more
Persons 17
| Date | First Name | Last Name | Title | Location | |||
| - | Sarah | Hernandez | Senior Exe... | - | - | - | |
| - | Caleb | Kreutner | Senior Vic... | - | - | - | |
| - | Brendon | Dobbs | Vice Presi... | - | - | - | |
| - | Ramona | Mullen | Chief of S... | - | - | - | |
| - | Catherine | Shoults, P... | Senior Vic... | - | - | - | |
| - | Trevor | Goethe | Associate,... | - | - | - | |
| - | Aleksei | Cremo | Principal,... | - | - | - | |
| - | Sandy | Zweifach | Operating ... | - | - | - | |
| - | Chidozie | Ugwumba | Founder &a... | - | - | - | |
| - | Allie | Ivy, PhD | Associate,... | - | - | - |
Show more
Mentions in press and media 18
| Date | Title | Description |
| 16.07.2026 | AdvanCell Closes $315 Million Series D | BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscribed and upsized $315 million Series D financing. >> Click here for more funding data on AdvanCell >> To export AdvanCel... |
| 15.07.2026 | AdvanCell Closes US $315M in Series D Funding | AdvanCell, a Boston, MA- and Brisbane, Australia-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised US $315M Series D in funding. The round was led by Ally Bridge Group and Alpha Wave, al... |
| 15.07.2026 | AdvanCell Closes $315 Million Series D Financing To Advance Targeted Alpha Therapies | AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, announced the closing of an oversubscribed and upsized $315 million Series D financing. The round was led by Ally Bridge Group and co-le... |
| 11.07.2026 | FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug | FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor... |
| 10.07.2026 | FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib | FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi... |
| 16.06.2026 | SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine | SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The inv... |
| 10.06.2026 | SonoThera Raises $125M in Series B Funding | SonoThera, a South San Francisco, CA-based biotechnology company developing new genetic medicines, raised $125M in Series B funding. The round was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bay... |
| 10.06.2026 | SonoThera Raises $125 Million Series B To Advance Ultrasound-Mediated Genetic Medicines | SonoThera, a biotechnology company developing ultrasound-mediated nonviral genetic medicines, announced the closing of an oversubscribed $125 million Series B financing round to support the clinical advancement of its lead programs for Duch... |
| 26.01.2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding. Backers included new investors includi... |
| 28.12.2025 | Aeovian Pharmaceuticals Secures $55M Series B for Groundbreaking Epilepsy Treatment | Aeovian Pharmaceuticals secured a significant $55 million Series B funding. This pivotal investment propels its lead candidate, AV078, into a Phase 2 study. AV078 is a first-in-class CNS-penetrant selective mTORC1 inhibitor. It targets seve... |
Show more